Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 12, 2007 - Issue 4
Submit an article Journal homepage
130
Views
14
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of metastatic renal cancer

Wolfram E Samlowski Head, Section of Melanoma, Renal Cancer and Immunotherapy Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA +1 702 822 5215; +1 702 944 2347; [email protected]
, MD &
Nicholas J Vogelzang Director Nevada Cancer Institute, Las Vegas, Nevada, One Breakthrough Way, Las Vegas, NV 89135, USA
, MD
Pages 605-618 | Published online: 05 Nov 2007

Bibliography

  • LINEHAN WM, BATES SE, YANG JC: Cancer of the kidney. In: Cancer: Principles and Practice of Oncology. (Volume 7). DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott, Williams & Wilkins, Philadelphia, USA (2006):1139-1167.
  • BUKOWSKI RM: Immunotherapy in renal cell carcinoma. Oncology (1999) 13(6):801-810.
  • JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. Cancer J. Clin. (2007) 57:43-66.
  • MOORE LE, WILSON RT, CAMPLEMAN SL: Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest. (2005) 23(3):240-255.
  • KIM HL, BELLDEGRUN AS, FREITAS DG et al.: Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J. Urol. (2003) 170(5):1742-1746.
  • COHEN HT, MCGOVERN FJ: Renal-cell carcinoma. N. Engl. J. Med. (2005) 353(23):2477-2490.
  • MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335(12):865-875.
  • LEONARD WJ: Type I cytokines and interferons and their receptors. In: Fundamental Immunology. Paul WE (Ed.), Lippincott, Williams & Wilkins, Philadelphia, USA (2003):701-748.
  • WEISS A: T lymphocyte activation. In: Fundamental Immunology. Paul WE (Ed.), Raven Press, NY, USA (1993):467-504.
  • LOTZE MT, GRIMM EA, MAZUMDER A, STRAUSSER JL, ROSENBERG SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. (1981) 41:4420-4425.
  • RAYNER AA, GRIMM EA, LOTZE MT, WILSON DJ, ROSENBERG SA: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J. Natl. Cancer Inst. (1985) 75:67-75.
  • HANK JA, KOHLER PC, WEIL-HILLMAN G et al.: In vivo induction of the lymphokine-activated killer phenomenon: IL-2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Res. (1988) 48:1965-1971.
  • PAPA MZ, MULÉ JJ, ROSENBERG SA: Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res. (1986) 46:4973-4978.
  • LAFRENIERE R, ROSENBERG SA: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. (1985) 45:3735-3741.
  • ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271:907-913.
  • FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, FYFE G: High-dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J. Sci. Am. (1997) 3:S70-S72.
  • YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
  • SIEGEL JP, PURI RK: Interleukin-2 toxicity. J. Clin. Oncol. (1991) 9:694-704.
  • ROSENSTEIN M, ETTINGHAUSEN SE, ROSENBERG SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. (1986) 137:1735-1742.
  • SAMLOWSKI WE: Nitric oxide as a mediator of interleukin-2 induced cardiovascular toxicity and antitumor activity. In: Nitric Oxide and Inflammation. Salvemini D, Billiar TR, Vodovotz Y (Eds), BirkhÄuser Publishing Ltd, Basel, Switzerland (2001):249-272.
  • MAHER ER, WEBSTER AR, RICHARDS FM et al.: Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J. Med. Genet. (1996) 33(4):328-332.
  • SEIZINGER BR, ROULEAU GA, OZELIUS LJ et al.: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature (1988) 332(6161):268-269.
  • LATIF F, TORY K, GNARRA J et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 260(5112):1317-1320.
  • HERMAN JG, LATIF F, WENG Y et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA (1994) 91(21):9700-9704.
  • DUAN DR, HUMPHREY JS, CHEN DY et al.: Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA (1995) 92(14):6459-6463.
  • MAXWELL PH, WIESENER MS, CHANG GW et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399(6733):271-275.
  • COCKMAN ME, MASSON N, MOLE DR et al.: Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. (2000) 275(33):25733-25741.
  • GEORGE DJ, KAELIN WG Jr: The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. (2003) 349(5):419-421.
  • PANTUCK AJ, ZENG G, BELLDEGRUN AS, FIGLIN RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res. (2003) 9(13):4641-4652.
  • DANCEY JE: Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. (2006) 5(9):1065-1073.
  • SCHEID MP, MARIGNANI PA, WOODGETT JR: Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol. Cell Biol. (2002) 22(17):6247-6260.
  • PANTUCK AJ, SELIGSON DB, KLATTE T et al.: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 109(11):2257-2267.
  • WANG X, FLYNN A, WASKIEWICZ AJ et al.: The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J. Biol. Chem. (1998) 273(16):9373-9377.
  • THOMAS GV, TRAN C, MELLINGHOFF IK et al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. (2006) 12(1):122-127.
  • GAO N, FLYNN DC, ZHANG Z et al.: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. (2004) 287(2):C281-C291.
  • VAN DUYNE GD, STANDAERT RF, KARPLUS PA, SCHREIBER SL, CLARDY J: Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J. Mol. Biol. (1993) 229(1):105-124.
  • ROBB VA, KARBOWNICZEK M, KLEIN-SZANTO AJ, HENSKE EP: Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. (2007) 177(1):346-352.
  • XU G, ZHANG W, BERTRAM P, ZHENG XF, MCLEOD H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int. J. Oncol. (2004) 24(4):893-900.
  • ROSS JS, QIAN J, SHEEHAN C, JONES D, JENNINGS T: Elevated phosphorylated mammalian target of rapamycin (p-mtor) expression in human neoplasms. Proc. ASCO (2007) 25:S582 (Abstract).
  • HERNANDO E, CHARYTONOWICZ E, DUDAS ME et al.: The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. (2007) 13(6):748-753.
  • WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64(19):7099-7109.
  • KARASARIDES M, CHILOECHES A, HAYWARD R et al.: B-RAF is a therapeutic target in melanoma. Oncogene (2004) 23(37):6292-6298.
  • EISEN T, AHMAD T, FLAHERTY KT et al.: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer (2006) 95(5):581-586.
  • RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
  • ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
  • AMATO RJ, HARRIS P, DALTON M et al.: A Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proc. ASCO (2007) 25:S241.
  • SUN L, LIANG C, SHIRAZIAN S et al.: Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. (2003) 46(7):1116-1119.
  • BRITTEN CD, KABBINAVAR F, RANDOLPH HECHT J et al.: A Phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. (2007).
  • MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
  • MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
  • MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
  • ATKINS MB, HIDALGO M, STADLER WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. (2004) 22(5):909-918.
  • MOTZER RJ, HUDES GR, CURTI BD et al.: Phase I/II trial of temsirolimus combined with interferon a for advanced renal cell carcinoma. J. Clin. Oncol. (2007) 25(25):3958-3964.
  • HUDES G, CARDUCCI M, TOMCZAK P et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. (2007) 356(22):2271-2281.
  • YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
  • ESCUDIER B, KORALEWSKI P, PLUZANSKA A et al.: A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first line therapy in metastatic renal cell carcinoma. Proc. ASCO25:S2 (Abstract).
  • MOTZER RJ, BOLGER GB, BOSTON B et al.: Kidney cancer. Clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. (2006) 4(10):1072-1081.
  • CHOUEIRI TK, GARCIA JA, ELSON P et al.: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 110(3):543-550.
  • PEIFER C, KRASOWSKI A, HAMMERLE N et al.: Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. J. Med. Chem. (2006) 49(25):7549-7553.
  • GEORGE DJ: Phase II studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin. Cancer Res. (2007) 13(2 Part 2):S753-S757.
  • RINI BI, WILDING GT, HUDES G et al.: Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. Proc. ASCO (2007) 25:S242 (Abstract).
  • KIM S, ROSEN LS, COHEN EE et al.: A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. Proc. ASCO (2006) 24 (Abstract #5529).
  • COHEN EE, VOKES E, ROSEN LS et al.: A Phase II study of axitinib (AG013736[AG]) in patients (pts) with advanced thyroid cancers. Proc. ASCO (2007) 7:S301 (Abstract).
  • WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60(8):2178-2189.
  • VOGELZANG NJ, STERNBERG CN: Signal-transduction inhibitors in renal cell carcinoma. BJU Int. (2007) 99(5 Part B):1289-1295.
  • LOS M, ROODHART JM, VOEST EE: Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist (2007) 12(4):443-450.
  • ANTHONY LB, MCCALL J, NUNEZ J, O'DORISIO T, O'DORISIO S: An open-label Phase II clinical trial of PTK787 in patients with progressive neuroendocrine cancer. Proc. ASCO (2007) 25:S621 (Abstract).
  • HUTSON TE, DAVIS ID, MACHIELS JP et al.: Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a Phase II randomized discontinuation trial. Proc. ASCO (2007) 25:S242 (Abstract).
  • FRIEDLANDER M, HANCOCK KC, BENIGNO B et al.: Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancer: initial results of a Phase II study. Proc. ASCO (2007) 25:S289 (Abstract).
  • DREVS J, SIEGERT P, MEDINGER M et al.: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (2007) 25(21):3045-3054.
  • SRIDHAR SS, HOTTE SJ, MACKENZIE MJ et al.: Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II Consortium. Proc. ASCO (2007) 25:S258 (Abstract).
  • VAN HERPEN C, DREVS J, VAN CRUIJSEN H et al.: Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two Phase I studies. Proc. ASCO (2007) 25:S152 (Abstract).
  • BATCHELOR T, SORENSEN AG, ANCUKIEWICZ M et al.: A Phase II trial of AZD2171(cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Proc. ASCO (2007) 25:S75 (Abstract).
  • GINGRICH DE, REDDY DR, IQBAL MA et al.: A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. (2003) 46(25):5375-5388.
  • RUGGERI B, SINGH J, GINGRICH D et al.: CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. (2003) 63(18):5978-5991.
  • NAKAMURA K, TAGUCHI E, MIURA T et al.: KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. (2006) 66(18):9134-9142.
  • ESKENS FA, PLANTING A, VAN DOORN L et al.: An open-label Phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptors 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. Proc. ASCO (2007) 25:S83 (Abstract).
  • ROSEN LS, KURZROCK R, MULAY M et al.: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (2007) 25(17):2369-2376.
  • POLVERINO A, COXON A, STARNES C et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. (2006) 66(17):8715-8721.
  • SHERMAN SI, SCHLUMBERGER MJ, DROZ J et al.: Initial results from a Phase II trial of motesanib diphosphate (AMG-706) in patients with differentiated thyroid cancer (DTC). Proc. ASCO (2007) 25:S303 (Abstract).
  • WIEDMANN M, FEISTHAMMEL J, BLUTHNER T et al.: Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs (2006) 17(7):783-795.
  • TRAXLER P, ALLEGRINI PR, BRANDT R et al.: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. (2004) 64(14):4931-4941.
  • BHIDE RS, CAI ZW, ZHANG YZ et al.: Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem. (2006) 49(7):2143-2146.
  • KULIMOVA E, OELMANN E, BISPING G et al.: Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol. Cancer Ther. (2006) 5(12):3105-3112.
  • FIEDLER WM, GIACCONE G, LASHCH P et al.: Phase I trial of SU014813 in patients (pts) with advanced solid malignancies. Proc. ASCO (2007) 25:S143 (Abstract).
  • PATYNA S, LAIRD AD, MENDEL DB et al.: SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther. (2006) 5(7):1774-1782.
  • HEDBORN S, STEINBILD S, FROST A et al.: Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced tumors. Proc. ASCO (2007) 25:S161(Abstract).
  • MCCARTHY AA: Exelixis: integrated drug-discovery and development platform for human therapeutics. Chem. Biol. (2005) 12(4):407-408.
  • ARTAVANIS-TSAKONAS S: Accessing the Exelixis collection. Nat. Genet. (2004) 36(3):207.
  • SALGIA R, HONG DS, CAMACHO LH et al.: A Phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Proc. ASCO (2007) 25:S614 (Abstract).
  • MARCH RJ, MIRTSCHING B, MODI S, WERTHEIM M: A Phase II study of XL999 in patients (pts) with NSCLC. Proc. ASCO (2007) 25:S692 (Abstract).
  • PORTER LL, BURRIS HA, JONES SF et al.: Summary of results in patients with metastatic renal cell cancer (RCC) from Phase I studies of RAD001(everolimus). Proc. ASCO (2006) 24 (Abstract #14599).
  • JAC J, GIESSINGER S, KHAN M, WILLIS J, CHIANG S, AMATO R: A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc. ASCO (2007) 25:S261 (Abstract).
  • SMOLEWSKI P: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs (2006) 17(5):487-494.
  • ELIT L: Drug evaluation: AP-23573 – an mTOR inhibitor for the treatment of cancer. Drugs (2006) 9(9):636-644.
  • DESAI A, JANISCH L, BERK LR et al.: A Phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc. ASCO (2004) 22 (Abstract #3150).
  • CHAWLA SP, TOLCHER AW, STADDON AP et al.: Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced bone sarcomas. Proc. ASCO (2006) 24 (Abstract #9505).
  • SHAKED Y, KERBEL RS: Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. (2007) 67(15):7055-7058.
  • DHAM A, DUDEK AZ: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Proc. ASCO (2007) 25:S261 (Abstract).
  • SABLIN MP, BOUAITA L, BALLEYGUIER C et al.: Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. Proc. ASCO (2007) 25:S244 (Abstract).
  • GELINAS DS, BERNATCHEZ PN, ROLLIN S, BAZAN NG, SIROIS MG: Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. (2002) 137(7):1021-1030.
  • KROLL J, WALTENBERGER J: VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2(KDR). Biochem. Biophys. Res. Commun. (1998) 252(3):743-746.
  • SHCHORS K, EVAN G: Tumor angiogenesis: cause or consequence of cancer? Cancer Res. (2007) 67(15):7059-7061.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.